Related content

Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer

By        

International Journal of Oncology, Vol. 47, Iss. 5, 2015-01 ,pp. : 1711-1724

Spandidos Publications

Access to resources Recommend Favorite

A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 643-650

John Wiley & Sons Inc

Access to resources Recommend Favorite

Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells

By              

Oncology Letters, Vol. 10, Iss. 3, 2015-01 ,pp. : 1627-1631

Spandidos Publications

Access to resources Recommend Favorite

Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

By Bergman A.M.   Giaccone G.   van Moorsel C.J.A.   Mauritz R.   Noordhuis P.   Pinedo H.M.   Peters G.J.  

European Journal of Cancer, Vol. 36, Iss. 15, 2000-10 ,pp. : 1974-1983

Elsevier

Access to resources Recommend Favorite

Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses

By Liu Qing-Hua   Zhao Chen-Yan   Zhang Jing   Chen Ying   Gao Li   Ni Can-Yong   Zhu Ming-Hua  

Molecular Medicine Reports, Vol. 6, Iss. 4, 2012-10 ,pp. : 767-773

Spandidos Publications

Access to resources Recommend Favorite